At 4.3% CAGR, the Middle East & Africa Gastric Cancer Diagnostic Procedure Market is projected to be worth US$ 51.05 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Middle East & Africa gastric cancer diagnostic procedure market was valued at US$ 39.63 million in 2022 and is expected to reach US$ 51.05 million by 2028, registering a CAGR of 4.3% from 2022 to 2028. Rise in prevalence of gastrointestinal diseases and surging cases of Helicobacter Pylori Infection attributed to the Middle East & Africa gastric cancer diagnostic procedure market expansion.                       

Many market players and research institutes operating in the gastric cancer diagnostics market are developing advanced products to expand their product portfolios and increase their market shares. They invest significant amounts in R&D to develop advanced products. A few of the recent developments related to gastric cancer diagnostic platforms are mentioned below:

In February 2022, Mayo Clinic researchers used AI and informatics to discover a 32-gene signature that is a prognostic and predictive biomarker for patients suffering from gastric cancer. The study was published in the edition of Nature Communications.

Thus, such developments of AI-based gastric cancer diagnostics are likely to introduce new trends in the gastric cancer diagnostic procedure market during the forecast period.

On the contrary, shortage of medical laboratory professionals hurdles the growth of Middle East & Africa gastric cancer diagnostic procedure market progress.

Based on healthcare providers, the Middle East & Africa gastric cancer diagnostic procedure market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others. The Hospitals segment held 42.9% market share in 2022, amassing US$ 17.00 million. It is projected to garner US$ 21.43 million by 2028 to expand at 3.9% CAGR during 2022–2028.

Based on symptoms type, the Middle East & Africa gastric cancer diagnostic procedure market is segmented into symptomatic and asymptomatic. The Asymptomatic segment held 79.5% market share in 2022, amassing US$ 31.49 million. It is projected to garner US$ 40.20 million by 2028 to expand at 4.2% CAGR during 2022–2028.

Based on body fluid, the Middle East & Africa gastric cancer diagnostic procedure market is segmented into body fluid blood, urine, saliva, stomach wash/gastric juice, tissue and others. Blood segment held 54.1% market share in 2022, amassing US$ 21.46 million. It is projected to garner US$ 28.26 million by 2028 to expand at 4.7% CAGR during 2022–2028.

Based on Diagnostic procedure, the Middle East & Africa gastric cancer diagnostic procedure market is categorized into endoscopic procedure, biopsy and tissue tests, lab test, in-vitro diagnostic tests, imaging test, molecular diagnostics, multiplexing molecular diagnostics, immunoassay, and others. The imaging segment held 41.8% market share in 2022. It was assessed at US$ 16.55 million in 2022 and is likely to hit US$ 21.05 million by 2028, exhibiting a CAGR of 4.1% during the forecast period.

Based on offering, the Middle East & Africa gastric cancer diagnostic procedure market is segmented into instruments, reagents & consumables and services. Reagents & Consumables segment held 48.2% market share in 2022, amassing US$ 19.10 million. It is projected to garner US$ 24.02 million by 2028 to expand at 3.9% CAGR during 2022–2028.

Based on disease condition, the Middle East & Africa gastric cancer diagnostic procedure market is segmented into early gastric cancer and gastric cancer advanced types. The Gastric cancer advanced type segment held 80.2% market share in 2022, amassing US$ 31.80 million. It is projected to garner US$ 41.23 million by 2028 to expand at 4.4% CAGR during 2022–2028.

Based on country, the Middle East & Africa gastric cancer diagnostic procedure market has been categorized into the Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 33.95 % market share in 2022. It was assessed at US$ 13.45 million in 2022 and is likely to hit US$ 17.03 million by 2028, exhibiting a CAGR of 4.0% during the forecast period. 

Key players dominating the Middle East & Africa gastric cancer diagnostic procedure market are Bio-Rad Laboratories Inc; F. Hoffmann-La Roche Ltd; bioMerieux SA; Thermo Fisher Scientific Inc; Illumina Inc; and Vela Diagnostics Holding Pte Ltd among others.   

• In Mar-2022, Vela Diagnostics launched OncoKey SL 60 and 525 Plus Panels. These next-generation sequencing (NGS)-based panels are intended for detection of DNA and RNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens, for up to 64 samples in a single sequencing run.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com